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Protein stabilityImmunoglobulinsM (IgMs) are gaining increasing attention as biopharmaceuticals since their multivalent mode
of binding can give rise to high avidity. Furthermore, IgMs are potent activators of the complement system. How-
ever, they are frequently difﬁcult to express recombinantly and can suffer from low conformational stability.
Here, the broadly neutralizing anti-HIV-1 antibody 2G12 was class-switched to IgM and then further engineered
by introduction of 17 germline residues. The impact of these changes on the structure and conformational stabil-
ity of the antibodywas then assessed using a range of biophysical techniques. We also investigated the effects of
the class switch and germline substitutions on the ligand-binding properties of 2G12 and its capacity for HIV-1
neutralization. Our results demonstrate that the introduced germline residues improve the conformational and
thermal stability of 2G12-IgM without altering its overall shape and ligand-binding properties. Interestingly,
the engineered protein was found to exhibit much lower neutralization potency than its wild-type counterpart,
indicating that potent antigen recognition is not solely responsible for IgM-mediated HIV-1 inactivation.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Monoclonal antibodies (mAbs) are increasingly important thera-
peutics for the treatment of cancer as well as autoimmune and infec-
tious diseases. The clinical success of mAbs is based on their potential
to bind their antigens with high afﬁnity and speciﬁcity, their long
in vivo half-life and their effector functions such as antibody-
dependent cell-mediated cytotoxicity and complement-dependent
cytotoxicity. The majority of currently approved mAbs are full-size
IgGs (150 kDa), but smaller versions such as minibodies (80 kDa),
Fab fragments (50 kDa) or scFv derivatives (27 kDa) are emerging as
alternatives [1]. However, many of these new variants suffer from a
short half-life or the absence of binding sites for ligands that trigger
effector functions.43 1 47654 6050.
43 1 47654 6675.
nger), renate.kunert@boku.ac.at
. This is an open access article underAnother alternative to IgGs are IgMs. These large polymeric antibod-
ies (~970 kDa in their pentameric form) are of increasing importance as
therapeutics. IgMs are the ﬁrst antibodies to be produced during a hu-
moral immune response and thus tend to have low afﬁnity, but their
multivalent mode of binding allows for high avidity. Moreover, their
complex structure makes them very effective in activating the comple-
ment system [2]. It has been demonstrated that IgMs can be employed
in anti-cancer therapy [3–6], for combating microbial infections [7,8]
or the treatment of graft-versus-host disease [9]. IgMs are considered
to be difﬁcult to produce in cell factories or other expression platforms
[10,11], and the puriﬁed proteins frequently suffer from decreased
conformational stability and heterogeneity in oligomeric structure.
However, a human IgM has been recently produced in a commercially
feasible scale [12].
Here we have investigated how the introduction of germline resi-
dues into a human immunodeﬁciency virus type 1 (HIV-1)-neutralizing
IgMmodiﬁes its conformational and thermal stability as well as antigen
binding and neutralization potency. The IgG version of the broadly neu-
tralizing anti HIV-1 mAb 2G12 [13] exhibits a unique domain-swappedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1a
Germline IGHV3-21/JH3 residues introduced into the variable regions of the heavy chain
of IgM-012 leading to IgM-012_GL. Amino acids previously identiﬁed as structurally or
functionally important [32–37] were kept unchanged.
Position 2G12 IGHV3/JH3 Change Reasoning
14 A P No Crucial for domain exchange [34]
19 I R No Hydrophobic patch in VH/VH′
interface [33]
23 G A G N A
24 V A V N A
26 N G No N might contribute to conformation
28 R T No Vernier zone [37]
29 I F No Vernier zone [37]
31 A S No Contact with antigen [33,34]
32 H Y No Contact with antigen [33,34]
33 T S No Contact with antigen [33,34]
39 R Q No Crucial for domain exchange [34]
40 V A V N A
43 G K No Positioned in VH/VL interface [34]
49 A S No Vernier zone [37]
52A T S No Contact with antigen [33]
55 T S No Contact with antigen [34]
57 R I No Important in VH/VH′ interface [33]
58 D Y No Important according to [33]
62 A S No Both residues small and uncharged
69 V I No Vernier zone [37]
73 D N No Vernier zone [37]
74 L A L N A
75 E K No Crucial for domain exchange [34]
76 D N D N N
77 F S No Hydrophobic patch in VH/VH′
interface [33]
78 V L No Vernier zone
82A H N H N N
82B K S K N S
82C M L M N L
84 V A No V stabilizes structure [33]
89 I V I N V
105 P Q No Unique structural properties of P
108 V M V NM
113 P S No Important for domain swap [33]
Table 1b
Germline IGKV1-5/JK1 residues introduced into the variable regions of the light chain of
IgM-012 leading to IgM-012_GL. Amino acids previously identiﬁed as structurally or func-
tionally important [32–37] were kept unchanged.
Position 2G12 IGKV1-5/JK1 Change Reasoning
2 V I I N V
3 V Q Q N V
18 T R T N R
19 I V I N V
30 E S No Vernier zone [37]
31 T S No Canonical residue [37]
53 T S No Speciﬁcity-determining residue [37]
55 K E No Speciﬁcity-determining residue [37]
56 T S No Speciﬁcity-determining residue [37]
77 G S G N S
80 F P F N P
87 H Y No H unusual at this position
90 H Q No Canonical residue [37]
92 A N No Speciﬁcity-determining residue [37]
93 G S No Contact with antigen [33]
96 A W No Speciﬁcity-determining residue [37]
103 R K R N K
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cluster of high-mannose N-glycans exposed on the viral envelope. A
class switch from IgG to IgM improved virus neutralization substantially
[14]. However, considerable heterogeneity was observed with respect
to the oligomeric state of 2G12-IgM, which was attributed to a reduced
conformational stability [15]. In thepresent study, a number of germline
residues was selected by rational design and then incorporated into
2G12-IgM to improve the biochemical properties of the protein. Alto-
gether, 17 changes were introduced into the framework of the variable
domains of the heavy and light chains, aiming at an increase of protein
stability while preserving antigen recognition. A thorough biophysical
comparison of 2G12-IgG and its two IgM variants enabled us to deter-
mine the conformational and thermal stability of the three recombinant
proteins and elucidate their unfolding pathways. Additionally, structur-
al information was derived from small-angle X-ray scattering (SAXS)
studies. Finally, the ligand-binding properties of wild-type and variant
2G12-IgMs were assessed by ELISA and neutralization assays.
2. Materials and methods
2.1. Cloning and establishment of cell lines
Highly puriﬁed 2G12-IgG was a gift from Polymun Scientiﬁc
(Immunbiologische Forschung GmbH, Klosterneuburg, Austria). The
generation of CHO lines producing wild-type 2G12-IgM (IgM-012) as
well as a control antibody (IgM-617) was described previously [16].
The germline variant of 2G12-IgM (IgM-012_GL) was designed accord-
ing to standard humanization strategies for monoclonal antibodies [17].
Brieﬂy, the germline genes with the highest similarity to vH and vL of
IgM-012were identiﬁed as IGHV3-21/JH3 and IGKV1-5/JK1, respective-
ly, using the online tool IMGT/V-QUEST [18,19] and aligned with the
variable regions of IgM-012 using CLUSTAL 2.0.8. Suitable replacements
were then chosen based on a superimposition of an IgM-012 model
with the structure of 2G12-IgG (PDB: 1OM3) using Swiss-PDBViewer
[20]. Finally, codon-optimized sequences (Life Technologies) were
cloned into bi-cistronic pIRES vectors (Clontech, # 631621) and used
for transfection of CHO DG44 cells (Invitrogen, # A10999-01) to estab-
lish a CHO cell line producing IgM-012_GL, as described previously
[14,16].
Recombinant cell lines were routinely cultivated in chemically
deﬁned ProCHO5 medium (Lonza, # BE12-766Q) supplemented
with 4 mM L-glutamine (Biochrom, # K0302), 15 μg/mL phenol red
(Sigma-Aldrich, # P0290), 0.5 mg/mL G418 (PAA, # P11-012) and
100 nM methotrexate (Sigma-Aldrich, # M8407) [15].
2.2. Puriﬁcation of IgMs
Collected cell-culture supernatants were concentrated by ultra-
diaﬁltration using a Millipore Labscale™ TFF System (Millipore, #
XX42LSS12). In the case of IgM-617, the concentrate was stored
overnight at 4 °C [21] followed by centrifugation at 8000 g for
30 min at 4 °C. Precipitated IgM-617 was dissolved in 0.2 M
NaHCO3, 0.15 M NaCl (pH 8.5) containing 3 M urea and then dia-
lyzed against 0.2 M NaHCO3, 0.15 M NaCl (pH 8.5).
IgM-012 and IgM-012_GL concentrates were subjected to afﬁnity
chromatography using IgM CaptureSelect Afﬁnity Matrix (Life Technol-
ogies, # 289010). 0.1 M glycine (pH 3.0) was used as elution buffer.
Eluted IgMs were immediately neutralized to pH 7.0 using Tris–HCl
(pH 9.5). Finally, dialysis against 0.2 M NaHCO3, 0.15 M NaCl (pH 8.5)
was performed.
Puriﬁed protein sampleswere loaded onto NuPage® gradient 3–12%
Bis–Tris gels (Life Technologies, # BN1001BOX) and run at 200 V for
60 min in Tris-Acetate SDS buffer (Life Technologies, # LA0041). Gels
were stained either with silver [22] or Sypro® Ruby (Bio-Rad Laborato-
ries, # 170-3126) [15,23]. NativeMark™ unstained protein standard
(Life Technologies, # LC0725) was used to estimate the molecularmass of the IgM bands. Densitometric analysis of silver-stained gels
was done using Quantity One (Bio-Rad).
2.3. Electronic circular dichroism spectroscopy
Overall secondary structure composition as well as temperature-
mediated unfolding was investigated by electronic circular dichroism
(ECD) spectroscopy (Chirascan, Applied Photophysics). The instrument
Fig. 1. Sequence alignment and structural model of 2G12-IgM. A) Alignment of IgM-012 and the respective germline sequences IGHV3-21/JH3 and IGKV1-5/JK1 using Clustal 2.0.8. Se-
quences are numbered according to the Kabat system. Complementarity-determining regions are in bold letters. Canonical residues are underlined and Vernier residues are marked by
asterisks. Residues previously identiﬁed as structurally and functionally important [32,34] are displayed in red. (B) Superimposition of 2G12-IgG (PDB identiﬁer: 1OM3) with models
of IgM-012_GL heavy and light chains. The introduced germline residues and their wild-type counterparts are displayed in blue and red, respectively. Note that in the model of the
IgM-012_GL heavy chain, the CH1 domain does not overlap with that of 2G12-IgG due to differences in the orientation of a ﬂexible loop.
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Temperature-mediated denaturation was monitored between 20 °C
and 90 °C with a heating rate of 1.0 °C min−1. For overall secondary
structure determination, wavelength scans between 190 and 260 nm
were performed. Temperature-mediated unfolding was studied at
218 nm (spectral bandwidth 3.0 nm; scan time per point: 12.5 s). Sam-
ples were analyzed in 0.2 M NaHCO3, 0.15 M NaCl (pH 8.5).
2.4. Differential scanning calorimetry
Differential scanning calorimetry (DSC) was performed on a
Microcal VP-capillary DSC microcalorimeter (GE Healthcare) equipped
with a 96-well plate autosampler. Samples (cell volume: 137 μL)
underwent programmed heating, using a scan rate of 60 °C h−1 over
the temperature range of 20 °C to 110 °C. Collected DSC data were
corrected for the buffer baseline and normalized for protein concentra-
tion. Heat capacity (Cp) was expressed in kcal mol−1 K−1 (1 cal =
4.184 J). Data points were ﬁtted to non-two-state unfolding models.
Samples were measured in 0.2 M NaHCO3, 0.15 M NaCl (pH 8.5).
2.5. Fluorescence spectroscopy
Chemical unfolding in the presence of increasing concentrations of
urea (Sigma-Aldrich, # U5378) was followed by ﬂuorescence spectros-
copy on an F-7000 Fluorescence Spectrophotometer (Hitachi) bymonitoring changes in the intrinsic ﬂuorescence of tryptophan residues
(excitation wavelength: 295 nm; emission wavelength: 300 – 450 nm;
scan speed: 60 nmmin−1; PMT voltage: 700 V; response: 0.5 s).
2.6. Small-angle X-ray scattering
All small-angle X-ray scattering (SAXS) datawere recorded on an in-
house instrument (SAXSess mc2, Anton Paar) equipped with a Kratky
camera, a sealed X-ray tube source and a two-dimensional Princeton In-
struments PI•SCX:4300 CCD detector (Roper Scientiﬁc). The scattering
patterns were measured with 180 min exposure times (1080 frames,
each 10 s) for several solute concentrations in the range of 1–
10 mg/mL. Radiation damage was excluded based on a comparison of
individual frames of the 180 min exposures. A range of momentum
transfer of 0.012 b s b 0.63 Å−1 was covered (s= 4π sin(θ) / λ, where
2θ is the scattering angle and λ= 1.5 Å is the X-ray wavelength). All
SAXS data were analyzed with the package ATSAS (version 2.5). The
data were processed with the SAXSQuant software (version 3.9), and
desmeared using the programs GNOM [24] and GIFT [25]. Forward scat-
tering intensity (I (0)), radius of gyration (Rg), maximum dimension
(Dmax) and the inter-atomic distance distribution function (P(R))
were computed with the program GNOM. The masses of the solutes
were evaluated by comparison of the forward scattering intensity
with that of a human serum albumin reference solution of known
concentration (molecular mass 66.5 kDa) and using Porod's law. To
Fig. 2. SDS-PAGE of 2G12-IgM. Puriﬁed IgM-012, IgM-012_GL and IgM-617 (control)were
separated on 3–12% gradient NuPage® Bis-Tris gels and detected by silver staining.
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culated using the program DAMMIF [26] and aligned, and averaged
using the program DAMAVER [27] assuming ﬁve-fold symmetry.
2.7. ELISA
96-well plates were coated with 2 μg/mL (100 ng/well) of sheep
anti-gp120 antibody (Aalto, # D7324) and incubated overnight at 4 °C.
After washing and blockingwith 4% non-fat dry milk in PBS (containing
0.05% Tween-20) for 1 h at 37 °C, plates were further incubated with
50 ng per well of soluble HIV-1 BG505 SOSIP.664 gp140 [28] for 2 h at
37 °C. Plates were thenwashed and subsequently incubatedwith serial-
ly diluted (1:4) antibody samples (starting at 10 μg/mL). After 1 h at
37 °C, the plates were washed, and bound antibody was detected with
a goat anti-human IgG + IgA + IgM-peroxidase conjugate (Jackson
ImmunoResearch, # 109035064). Finally, plates were washed, devel-
oped with 3,3′,5,5′-tetramethylbenzidine as substrate, and analyzed
with a BioTek plate reader at 450 nm. EC50 values were calculated
using GraphPad Prism 5.0 software for Windows (GraphPad Software).
2.8. Neutralization assays
Pseudotyped virions were generated as described previously [29].
In brief, 5 × 105 human embryonic kidney 293T cells (ATCC, # CRL-
3216)were co-transfectedwith 4 μg of the HIV-1 envelope glycoprotein
(Env)-deleted backbone plasmid pSG3ΔEnv (NIHARRRP; contributed
by J. Kappes and X. Wu) and 2 μg of the respective HIV-1 Env comple-
mentation kiplasmid using polyethyleneimine (18 μg) as a transfection
reagent. Cell culture supernatants were harvested 48 h after transfec-
tion, cleared by centrifugation at 4000 g for 10 min, and then used forsingle-round infectivity assays as described elsewhere [30]. Brieﬂy,
pseudotyped virus was added at a 1:1 volume ratio to serially diluted
(1:3) mAbs (starting at 40 μg/mL) and incubated at 37 °C. After 1 h
TZM-bl reporter cells (NIH AIDS Reagent Program, # 8129) were
added (1:1 by volume) at 1 × 104 cells/well, supplemented with
10 μg/mL DEAE-dextran and then incubated for a further 48 h at
37 °C. Next, the cells were washed, lysed, and developed with lucif-
erase assay reagent according to the manufacturer's instructions
(Promega). Relative light units were then measured using a micro-
plate luminometer (BioTek, Synergy 2 luminescence microplate
reader). All experiments were performed at least in duplicate. The
extent of virus neutralization in the presence of antibody was deter-
mined as the 50% inhibitory concentration (IC50) as compared to
samples treated without mAb.
3. Results
3.1. Design and production of engineered 2G12-IgM
The rational design of IgM-012_GL was based on the primary se-
quence of IgM-012. Tenmutationswere introduced into the framework
of IgM-012 vH and 7 mutations into that of IgM-012 vL (Tables 1a and
1b). In essence, all residues were changed into their germline counter-
parts except those which are (i) known to be important for antigen
binding (as identiﬁed by previous studies), (ii) located in Vernier
zones, and (iii) responsible for the unique domain swap of 2G12
(Fig. 1, Tables 1a and 1b). While the percentage of identities between
IgM-012 and the corresponding germline sequences is 68% (vH) and
84% (vL), these values increase to 78% and 91% in the case of IgM-
012_GL, leading to an improvement of the germinality index [31] from
0.8 (IgM-012) to 0.9 (IgM-012_GL). However, the natural IgM-617 dis-
plays an even higher extent of homology with its germline counterpart
(vH: 95%; vL: 98%). It should be noted that the mutations introduced
into IgM-012 did not lead to substantial changes in hydrophobicity
(IgM-012: 244 hydrophobic residues; IgM-012_GL: 243 hydrophobic
residues; total number of residues in both cases: 789) and isoelectric
point (IgM-012: 6.72; IgM-012_GL: 6.81).
Bi-cistronic pIRES vectors containing the engineered sequences
were used for transfection of CHODG44 cells [12,14], giving rise to a sta-
ble CHO cell line producing IgM-012_GL. IgM-012 and IgM-012_GL
could be puriﬁed in good yields and were found to be highly soluble
(N10 mg/mL). SDS-PAGE combined with densitometric analysis re-
vealed that puriﬁed IgM-012 consists of 68 ± 5% pentamers, 26 ± 3%
hexamers and 5 ± 3% dimers (n = 3). Despite the replacement of 17
residues, assembly of IgM-012_GL into pentamers (58 ± 6%) and
hexamers (23 ± 1%) is remarkably efﬁcient, with only a moderate
increase in dimers amounting to 19 ± 5% (n = 4; Fig. 2). However, it
cannot be completely ruled out that the observed small differences in
oligomer distribution might exert subtle effects on the biophysical and
functional properties of the proteins.
3.2. Thermal and chemical stability
Next we probed the overall secondary structure and thermal
stability of 2G12-IgG, IgM-012, IgM-012_GL and a natural IgM
(IgM-617) by ECD spectroscopy. The far-UV spectra of these proteins
were similar, exhibiting a minimum at 218 nm, which is typical for
protein structures dominated by β-sheets (Fig. 3A left panel). Upon
increasing the temperature to N80 °C, the proteins unfolded irrevers-
ibly leading to far-UV spectra of increased ellipticity with a broad
minimum between 205 and 220 nm (dashed lines in Fig. 3A, left
panel). This indicates the residual presence of undeﬁned structural
elements after thermal denaturation of the antibodies, which agrees
well with the observation that protein precipitation did not occur.
Similar results were previously reported for antibodies of different
isotypes [32].
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with Tm values of 57.1 ± 0.1 °C (Tm1) and 67.3 ± 0.2 °C (Tm2). The cor-
responding van't Hoff enthalpies were calculated to be 382 ±
4 kJ mol−1 and 356 ± 16 kJ mol−1, respectively (Fig. 3A right panel).
By contrast, its class-switched counterpart IgM-012 unfolds with a
broad transition range between ~40 °C and ~65 °C (Tm 52.8 ± 0.5 °C,
van't Hoff enthalpy 241 ± 6 kJ mol−1). Closer inspection shows the oc-
currence of an unfolding intermediate (which is even more evident
upon analysis with DSC as demonstrated below). In the case of IgM-
012_GL, ECD suggests that the unfolding pathway follows a two-state
transition within a smaller temperature range, pointing to a mode ofFig. 3. Temperature-mediated unfolding of 2G12 variants. A) Electronic circular dichroism spec
native state (continuous lines) and in the completely unfolded state (at 80 °C; dashed lines). Te
van't Hoff plots. B) Differential scanning calorimetry. Thermograms are depicted with ﬁts (red l
ΔH gives information about the cooperativity of a transition (ΔHv/ΔH b 1, non-cooperative; ΔHcooperative unfolding (Tm 55.7 ± 1.1 °C, van't Hoff enthalpy 383 ±
4 kJ mol−1). The natural IgM-617 used for comparisonwas found to ex-
hibit a Tm value of 60.4 ± 0.2 °C and a van't Hoff enthalpy of about
515 kJ mol−1 (Fig. 3A right panel).
To further investigate these observed differences in thermal stability,
DSC was performed (Fig. 3B). 2G12-IgG clearly shows two main transi-
tions at 65 °C (Tm1) and 77 °C (Tm2), whereas the endotherm of IgM-
012 could be best ﬁtted by three transitions with Tm values of 53 °C,
60 °C, and 77 °C. By introduction of the germline residues, both the
cooperativity and thermal stability of IgM-012_GL increased signiﬁcant-
ly (Tm1 = 64 °C, Tm2 = 72 °C) and became similar to that of IgM-617troscopy. Far UV-spectra of 2G12-IgG, IgM-012, IgM-012_GL, and IgM-617 (control) in the
mperature-mediated unfolding was followed at 218 nm. Insets display the corresponding
ine) based on the assumption of non-two-state (i.e. multi-step) transitions. The ratioΔHv/
v/ΔH N 1, cooperative unfolding).
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617 the ratio of van't Hoff enthalpy and calorimetric enthalpy calculated
fromDSC experiments suggested a non-cooperative unfolding event for
the ﬁrst transition (ΔHv/ΔH b 1) and a cooperative unfolding for theTable 2
Calorimetric enthalpies and van't Hoff enthalpies derived from differential scanning calo-
rimetric measurements (see Fig. 3B).
Tm (°C) ΔH (cal mol−1) ΔHv (cal mol−1) ΔHv/ΔH
IgG-2G12 64.8 4.3 × 105 1.1 × 105 0.26
76.7 8.0 × 104 1.7 × 105 2.13
IgM-012 53.4 6.4 × 105 5.7 × 104 0.09
60.1 1.0 × 106 1.3 × 105 0.13
70.1 8.4 × 104 1.8 × 105 2.14
IgM-012_GL 64.3 3.3 × 106 1.3 × 105 0.04
71.8 2.3 × 105 2.7 × 105 1.17
IgM-617 66.7 4.0 × 105 1.3 × 105 0.33
70.2 1.5 × 106 1.6 × 105 1.07second transition (ΔHv/ΔH N 1) (Table 2). Typically, Tm values obtained
from DSC were higher compared to those derived from ECD. The latter
allows direct temperature control in the cuvette, whereas in DSC
measurements higher scan rates may result in overestimation of Tm
values. Importantly, the hierarchy of Tm values of investigated proteins
is the same for both methods.
Finally, the conformational stability was probed by chemical dena-
turation of the four recombinant antibodies using increasing concentra-
tions of urea (0–8 M). The change in tryptophan ﬂuorescence intensity
wasmonitored spectroﬂuorimetrically. Fig. 4 depicts the corresponding
curves demonstrating that 2G12-IgG is stable up to 5 M urea. Unfolding
starts at 5.5 M urea, but does not reach completion even at the highest
urea concentration used (8 M). Its IgM counterpart IgM-012 already
shows some minor unfolding between 1 and 4 M urea, but this is
again followed by a steady increase in ﬂuorescence without achieving
an upper plateau. The presence of germline residues in IgM-012_GL
only slightly increased its chemical stability, with the ﬁrst (minor) tran-
sition being less pronounced than in the case of its wild-type counter-
part. These data are comparable to natural IgM-617 that also follows a
non-two-state transition with a ﬁrst (minor) unfolding event below
3 M and a second (major) one within the range of 4–7 M urea (Fig. 4).3.3. SAXS studies
For further structural evaluation small-angle X-ray scattering
(SAXS) was employed. The raw data (Fig. 5A) already allows to clearly
discriminate between IgM-617 and the two 2G12-IgM variants, for
which almost identical scattering curves were obtained. This is further
supported by the calculated gyration radius (Rg) values showing that
IgM-012 and IgM-012_GL adopt a less compact fold than IgM-617
(Fig. 5B). Notably, the determined Rg values are in good agreement
with those of previous SAXS experiments on IgMs [33,34]. A ﬁve-fold
symmetry was imposed for low-resolution shape modeling of IgM-
012 and IgM-617, and a total of 50 structures were used to generate
density models. In agreement with the scattering curves and the pair
distance distribution function, the superimposition of the shapemodels
conﬁrms that IgM-617 adopts a more compact conformation than IgM-
012 and IgM-012_GL (Fig. 5C).3.4. Ligand-binding properties and neutralization activity of 2G12-IgM
Next we compared the ligand-binding properties of 2G12-IgG, IgM-
012 and IgM-012_GL. Binding to trimeric HIV-1 envelope glycoprotein
BG505 SOSIP.664 gp140 (which has an architecture very similar to
that of native envelope spikes on HIV-1 virions) was assessed by
ELISA. As documented by the binding curves depicted in Fig. 6, IgM-
012_GL is still able to bind efﬁciently to HIV-1 gp140. There is a 1.6-
fold difference in EC50 values between IgM-012 (EC50 = 0.12 μg/mL)
and IgM-012_GL (EC50 = 0.20 μg/mL), suggesting only a minimal loss
in afﬁnity. Based on protein concentration, the EC50 of 2G12-IgG for
HIV-1 gp140 is considerably lower (0.02 μg/mL) than that of either
IgM. However, it is possible that due to steric hindrance only one bind-
ing site per IgMmolecule is reactive in our ELISA system. In terms ofmo-
larity, the ligand-binding capacity of the IgM and IgG molecules would
then be comparable, as the molar mass of IgM-012 and IgM-012_GL
is N5 times higher than that of 2G12-IgG.
Finally, the neutralization activity and breadth of the 2G12 mAbs
were evaluated using a panel of pseudotyped HIV-1 isolates from clades
B, C and E. IgM-012 was able to neutralize all tested clade B isolates at a
median IC50 of 0.1 μg/mL. 2G12-IgG, which neutralized all clade B virus-
es except ADA, revealed a 10-fold highermedian IC50 value (1.0 μg/mL).
By contrast, IgM-012_GL neutralized only one clade B isolate (TRO.11)
with high potency. None of the above mentioned mAbs neutralized
HIV-1 strains from clades C and E (Table 3).
Fig. 4. Urea-mediated unfolding of 2G12 variants. Change in intrinsic ﬂuorescence upon addition of increasing concentrations of urea. Note that only the control IgM (IgM-617) could be
completely unfolded. For the othermAbs, the upper plateau of theunfolding curve could not bedetermined.Hence, comparative estimates for the conformational stability of the antibodies
could not be deduced.
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In addition to the previously established CHO cell lines for produc-
tion of the mAbs IgM-012 and IgM-617 [16], in the present work a
CHO cell line was newly generated that expresses the germline variant
IgM-012_GL. Engineering of IgM-012 followed a rational approach
to avoid changes at amino-acid positions of importance either forFig. 5. Global shape of 2G12-IgM. (A) Experimental X-ray scattering data of IgMs. The s axis is s
imental radial density distributions of IgMs. Calculated Rg values are shown. (C)Models of IgM-0
by DAMMIF using an average of 50 structures, with P5 symmetry being imposed.antigen binding or for structural integrity [35–39]. The attempt was to
(i) increase its conformational and thermal stability, (ii) preserve anti-
body speciﬁcity and (iii) decrease the immunogenicity of IgM-012_GL
compared to the wild-type protein [39].
Since biogenesis of secretory IgMs is a stringently controlled process
involving several quality control checkpoints [40], the slightly increased
heterogeneity of IgM-012_GL with respect to its oligomerization statushown in a logarithmic representation. (B) SAXS data showing a comparison of the exper-
12, IgM-012_GL and IgM-617 (control) proteins and their overlay. Modelswere calculated
Fig. 6. Ligand-binding activity of 2G12 variants. Interaction of 2G12-IgG and 2G12-IgM
with trimeric BG505 SOSIP.664 HIV-1 gp140 as determined by ELISA.
1543V. Chromikova et al. / Biochimica et Biophysica Acta 1854 (2015) 1536–1544is more likely the consequence of undesirable fragmentation upon or
during secretion than of imperfect assembly in the endoplasmic reticu-
lum. Contamination with undesired proteolytic activity is a widespread
problem in mAb production [41], and it has been shown that reduced
conformational stability and elevated structural ﬂexibility can give rise
to a higher tendency of fragmentation [42].
The original IgG version of 2G12 iswell characterized andwas there-
fore included in this study for comparative purposes. Its antigen-
binding regions are intertwined on the top of the molecule due to a do-
main swap, resulting in the formation of a structurally unique Fab
dimer. In the gp140-bound state, the two Fab arms of 2G12-IgG were
shown to be also locked above the Fc suggesting no substantial change
upon ligand binding [43]. Temperature-mediated unfolding of 2G12-
IgG as monitored by both ECD and DSC followed a clear non-two-state
unfolding pathway with two domains of different sensitivity, re-
presenting the Fab and Fc fragments of the IgGmolecule [32]. By contrast,
urea-mediated unfolding monitored by ﬂuorescence spectroscopy
suggested only one main unfolding event. Upon class switch to IgM,
both the thermal and chemical stability of 2G12 decreased signiﬁcantly
and showed at least three transitions. This could indicate that IgM
sequences interfere with the swapping of the VH domains, since this
unique structural feature is known to contribute to the rigidity of the
2G12 molecule [35]. However, SAXS analysis of IgM-012 and IgM-
012_GL provided no evidence for inefﬁcient domain-swapping during
the assembly of 2G12-IgMs.
When compared with 2G12-IgG, a reduction was observed for the
ligand-binding capacity of IgM-012, with the EC50 value for binding of
HIV-1 gp140 increasing from0.02 μg/mL to 0.12 μg/mL. This could either
reﬂect an unanticipated steric hindrance affecting the antigen-binding
sites of 2G12 in the IgM format or be a direct consequence of the
reduced conformational stability of the protein. By introduction of
germline residues, the thermal stability and cooperativity of unfolding
of 2G12-IgM could be improved signiﬁcantly. The observation that
afﬁnity-matured antibodies exhibit a lower stability than their germlineTable 3
Neutralization potency of IgM and IgG variants of 2G12 towards pseudotyped HIV-1
isolates.
HIV-1 isolate (clade) IC50 [μg antibody/mL]
IgM-012 IgM-012_GL 2G12
JR-FL (B) 0.22 8.91 0.64
JR-CSF (B) 0.10 N10 0.95
SF162 (B) 0.07 N10 1.55
HxB2 (B) 0.08 N10 0.19
ADA (B) 0.31 N10 N10
PVO.4 (B) 0.10 N10 1.88
TRO.11 (B) 0.09 0.38 0.44
ZM53M (C) N10 N10 N10
ZM214M (C) N10 N10 N10
93TH966.8 (E) N10 N10 N10precursors has already been reported for other mAbs [44,45]. Impor-
tantly, IgM-012_GL still shows good gp140 recognition, with its EC50
being only ~1.6-fold higher than that of IgM-012, thus demonstrating
that ligand binding was only slightly compromised by the introduction
of the germline residues. This is in good agreement with SAXS experi-
ments indicating that the overall structure of IgM-012 and IgM-
012_GL is very similar.
The present study also established a higher HIV-1 neutralization po-
tency of IgM-012 as compared to 2G12-IgG, as evident from a 10-fold
difference in the median IC50 value for the 2G12-sensitive viral isolates
tested. With a median IC50 of 0.1 μg/mL, the neutralization potency of
IgM-012 is even better than that of the latest generation of broadly neu-
tralizing anti-HIV IgGs such as PG9 (median IC50 0.4 μg/mL) or VRC01
(median IC50 0.2 μg/mL). It has been observed previously that the im-
munological performance of 2G12 improves upon class switch from
IgG to IgM [14]. Although the effector functions of IgM-012 still remain
to be tested in detail, our ﬁndings highlight the anti-viral potential of
mAbs based on the IgM format. Despite being barely compromised in
its gp140-binding capacity, the stabilized variant IgM-012_GL has lost
most of its ability to neutralize HIV-1. Future studies will therefore
aim at identifying the introduced residues which account for this selec-
tive reduction in neutralization potency.
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